[Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
Uspenskiĭ
Iu P
IuP
Pakhomova
I G
IG
Bubiakina
V N
VN
D000464:Alginates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000863:Antacids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D050500:Pancreatitis, Chronic / Q000150:complications*; D012824:Silicic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017693:Sodium Bicarbonate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000464:Alginates; D000863:Antacids; D004338:Drug Combinations; D012824:Silicic Acid; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D017693:Sodium Bicarbonate